CNTB

Connect Biopharma Holdings Ltd

0.8022

Oct 30 • 3:59 PM ET -0.0332 (-3.97%)

0.7900

Aftermarket • 7:30 PM ET -0.0122 (-1.52%)

Healthcare Biotechnology USA Micro NASD

Peers: UPB REGN KYMR SNY EVMN ZURA INSM ORKA ALMS AZN

| Held by: IWM IWO IWN VTWO IWC VTWG VTWV RSSL ITWO URTY

Scroll to Statements

Index	RUT
Market Cap	50.51M
Enterprise Value	19.62M
Income	-68.99M
Sales	2.95M
Book/sh	0.43
Cash/sh	0.50
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	64
IPO	Mar 19, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	17.12
P/B	1.88
P/C	1.60
P/FCF	-
EV/EBITDA	-
EV/Sales	6.65
Quick Ratio	2.37
Current Ratio	2.37
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.20
EPS next Y	-0.81
EPS next Q	-0.27
EPS this Y	1.32%
EPS next Y	20.19%
EPS next 5Y	7.93%
EPS past 3/5Y	22.61% 12.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	-322.65%
Sales Y/Y TTM	-
EPS Q/Q	-18.29%
Sales Q/Q	5666.67%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	14.50% 271.31%

Insider Own	72.85%
Insider Trans	0.33%
Inst Own	27.30%
Inst Trans	5.50%
ROA	-109.34%
ROE	-140.51%
ROIC	-254.92%
Gross Margin	-
Oper. Margin	-2384.49%
Profit Margin	-2336.30%
SMA20	-7.37%
SMA50	-40.97%
SMA200	-63.44%
Trades

Shs Outstand	62.97M
Shs Float	17.10M
Short Float	22.56%
Short Ratio	0.99
Short Interest	3.86M
52W High	3.82 -79.00%
52W Low	0.73 9.61%
Volatility	9.13% 8.96%
ATR (14)	0.11
RSI (14)	32.96
Beta	0.02
Rel Volume	0.64
Avg Volume	3.90M
Volume	2,503,785

Perf Week	4.66%
Perf Month	-18.12%
Perf Quarter	-59.28%
Perf Half Y	-67.52%
Perf YTD	-71.55%
Perf Year	-48.25%
Perf 3Y	-39.68%
Perf 5Y	-94.94%
Perf 10Y	-
Recom	1.00
Target Price	6.03
Prev Close	0.84
Price	0.80
Change %	-3.97%

Consensus

Strong Buy

Avg. Price Target

$6.03

Implied Upside

+651.7%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Resumed	LLeerink Partners	Outperform	$4	+398.6%
Jun 26, 2026	Initiated	PPiper Sandler	Overweight	$7	+772.6%
May 26, 2026	Initiated	CCanaccord Genuity	Buy	$6	+647.9%
May 21, 2026	Initiated	CCantor Fitzgerald	Overweight	$4	+398.6%
Dec 01, 2025	Initiated	LLake Street	Buy	$9	+1,021.9%
Oct 31, 2025	Initiated	BBTIG Research	Buy	$10	+1,146.6%
Jun 12, 2025	Initiated	HH.C. Wainwright	Buy	$7	+772.6%
Mar 04, 2024	Initiated	HH.C. Wainwright	Buy	$7	+772.6%
Apr 13, 2021	Initiated	SSVB Leerink	Outperform	$32	+3,889.0%
Apr 13, 2021	Initiated	PPiper Sandler	Overweight
Apr 13, 2021	Initiated	JJefferies	Buy	$27	+3,265.7%

Sep-30-26 10:43AM	Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program (InvestorsHub) +10.89%
07:00AM	Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (GlobeNewswire)
Sep-15-26 11:01AM	Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance (InvestorsHub) -32.17%
07:00AM	Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation (GlobeNewswire)
Sep-03-26 04:05PM	Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -30.07%
04:05PM	Loading…
Aug-12-26 04:05PM	Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +9.01%
Jun-17-26 09:00AM	Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma (GlobeNewswire)
May-12-26 04:05PM	Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire) +14.53% -8.58%
09:00AM	Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-26 09:00AM	Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis (GlobeNewswire)
Mar-31-26 04:05PM	Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update (GlobeNewswire) -9.66%
Mar-30-26 07:02AM	Connect Biopharma Announces $20.2 Million Private Placement Financing (GlobeNewswire) -15.94%
07:01AM	Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study (GlobeNewswire)
07:00AM	Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD (GlobeNewswire)
Mar-10-26 09:00AM	Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire) +5.28%
09:00AM	Loading…
Mar-03-26 09:00AM	Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-26 06:46AM	Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference (MarketBeat)
Feb-19-26 09:00AM	Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-26 08:00AM	Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 (GlobeNewswire)
Nov-24-25 09:00AM	Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-12-25 09:00AM	Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.92%
Sep-29-25 09:00AM	Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 (GlobeNewswire) -16.64%
Sep-04-25 08:00AM	Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025 (GlobeNewswire) -10.55%
Sep-03-25 08:00AM	Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq (GlobeNewswire) -5.69%
Aug-27-25 09:00AM	Connect Biopharma to Present at Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-14-25 08:00AM	Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide (GlobeNewswire) -8.90%
Aug-13-25 09:00AM	Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-25 12:00PM	What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? (Zacks) +20.00%
Jul-22-25 09:00AM	Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors (GlobeNewswire) +19.00%
Jul-21-25 09:00AM	Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq (GlobeNewswire) +16.28%
09:00AM	Loading…
Jul-18-25 09:00AM	Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire) -7.53%
Jul-17-25 09:00AM	Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +14.81%
Jul-09-25 09:00AM	Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China (GlobeNewswire)
Jun-13-25 09:00AM	Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress (GlobeNewswire) +11.76%
Jun-03-25 09:00AM	Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress (GlobeNewswire)
May-28-25 09:00AM	Connect Biopharma to Present at Two Upcoming Investor Conferences in June (GlobeNewswire)
May-20-25 09:00AM	Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +8.12%
May-15-25 09:00AM	Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.58%
May-14-25 09:00AM	Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD (GlobeNewswire)
05:25AM	Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma (Clinical Trials Arena)
May-13-25 09:00AM	Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma (GlobeNewswire) -5.16%
Apr-24-25 09:00AM	Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +13.75%
Apr-01-25 09:00AM	Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart (GlobeNewswire)
Mar-31-25 04:05PM	Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (GlobeNewswire) -19.12%
09:00AM	Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update (GlobeNewswire)
Mar-28-25 04:05PM	Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) -10.53%
Mar-03-25 08:00AM	Connect Biopharma to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:30AM	Attovia Therapeutics Appoints Chief Financial Officer (GlobeNewswire) -10.00%
Sep-10-24 08:00AM	Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024 (GlobeNewswire)
Sep-05-24 04:05PM	Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.76% +5.05%
Jul-01-24 08:00AM	Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum (GlobeNewswire) -5.26%
Jun-12-24 06:03PM	Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.08%
04:15PM	Connect Biopharma Announces New Leadership and Chair of the Board of Directors (GlobeNewswire)
May-22-24 04:05PM	Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma (GlobeNewswire) -5.08% +7.14%
May-07-24 06:30AM	Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma (GlobeNewswire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile) +8.39%
Apr-16-24 04:05PM	Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.40%
Mar-19-24 08:30AM	Connect Biopharma to Participate in H.C. Wainwright 2 Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Feb-12-24 04:30PM	Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors (GlobeNewswire) -8.93%
Dec-12-23 06:00AM	Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma (GlobeNewswire) -9.11%
Dec-11-23 04:05PM	Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023 (GlobeNewswire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile) +13.86%
Nov-28-23 09:40AM	Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.93%
Nov-21-23 07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -38.83%
06:03AM	Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China (GlobeNewswire)
06:00AM	Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Nov-20-23 04:41PM	Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023 (GlobeNewswire)
Nov-06-23 09:40AM	Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year? (Zacks) +6.62%
Oct-20-23 09:40AM	Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year? (Zacks) -7.63%
Sep-15-23 12:00PM	Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -9.51%
Sep-12-23 04:15PM	Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Aug-24-23 06:21PM	Connect Biopharma to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Jul-10-23 08:00AM	Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology (GlobeNewswire)
Jul-05-23 04:05PM	Connect Biopharma to Participate in the SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-01-23 04:05PM	Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis (GlobeNewswire) +9.91%
Apr-11-23 04:05PM	Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.56%
Mar-20-23 09:24AM	Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions (Benzinga) +20.00%
Mar-18-23 02:40PM	Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms (Business Wire)
Mar-17-23 04:38PM	Connect Biopharma stock up more than 40% after trial data (MarketWatch) +20.00%
04:05PM	Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions (Business Wire)
Mar-06-23 08:15AM	Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Feb-06-23 08:30AM	Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California (GlobeNewswire)
Jan-16-23 05:13AM	Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-30-22 07:30AM	Connect Biopharma Provides Business and Clinical Development Program Update (GlobeNewswire) +11.06%
Dec-19-22 08:00AM	Connect Biopharma to Present at the San Francisco Biotech Showcase in January (GlobeNewswire)
Dec-02-22 05:00PM	Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) -5.40%
Oct-27-22 04:05PM	Connect Biopharma To Present at Upcoming Investor and Scientific Conferences (GlobeNewswire)
Oct-04-22 11:40AM	Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients (Benzinga) -15.27%
08:56AM	CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China (GlobeNewswire)
07:00AM	Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China (GlobeNewswire)
Oct-03-22 04:10PM	Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Sep-13-22 04:30PM	Edited Transcript of CNTB.OQ earnings conference call or presentation 13-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update (GlobeNewswire)
Sep-01-22 08:00AM	Connect Biopharma to Report First Half 2022 Financial Results on September 13 (GlobeNewswire)
Aug-30-22 09:36AM	Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile (Benzinga)
08:00AM	Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study (GlobeNewswire)
Aug-08-22 12:19PM	Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth? (Simply Wall St.) +23.48%
Jul-12-22 06:02AM	Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year (Benzinga) +5.34%
Jul-11-22 04:05PM	Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huang James	Director	May 29 '26	Buy	2.48	150,000	371,610	13,310,000	Jun 02 04:30 PM
Huang James	Director	Mar 31 '26	Buy	3.45	1,160,000	4,002,000	13,160,000	Apr 01 04:30 PM
Panacea Innovation Limited	10% Owner	Nov 24 '25	Proposed Sale	3.00	2,000,000	6,000,000		Nov 24 09:45 PM
Wei Zheng	10% Owner	Nov 21 '25	Proposed Sale	3.19	650,000	2,073,500		Nov 21 03:32 PM
BioFortune Inc	10% Owner	Nov 18 '25	Proposed Sale	2.49	500,000	1,245,000		Nov 18 07:06 AM

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.

CEO & DirectorDr. Barry David Quart Pharm.D.

PresidentMr. David L. Szekeres J.D.

Senior Vice President of FinanceMs. Lisa Peraza CPA

General Counsel & Corporate SecretaryMr. Jeff Cohn J.D.

Vice President of Human ResourcesMr. Sean T. Ristine

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTB

Connect Biopharma Holdings Ltd

Upgrade your Finviz experience